← TEVA PHARMACEUTICAL INDUSTRIES LTD

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations — — — — — — ($2.5b) ($615.0m) ($2.0b) $1.4b
Net Income (Loss) Attributable to Parent $311.0m ($16.3b) ($2.1b) ($999.0m) ($4.0b) $417.0m ($2.4b) ($559.0m) ($1.6b) $1.4b
Net Income (Loss) Available to Common Stockholders, Basic $311.0m ($16.5b) ($2.4b) ($999.0m) ($4.0b) — ($2.4b) ($559.0m) ($1.6b) $1.4b
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest — ($16.4b) ($2.5b) ($1.0b) ($4.1b) $456.0m ($2.4b) ($615.0m) ($2.0b) $1.4b
Net Income (Loss) Attributable to Noncontrolling Interest — ($184.0m) ($322.0m) ($2.0m) ($109.0m) $39.0m ($53.0m) ($56.0m) ($320.0m) $7.0m
Depreciation and amortization — $2.1b $1.8b $1.7b $1.6b $1.3b $1.3b $1.2b $1.1b $1.0b
Depreciation — $632.0m $676.0m $609.0m $537.0m $528.0m $576.0m $537.0m $471.0m $421.0m
Amortization — $1.4b $1.2b $1.1b $1.0b $802.0m $732.0m $616.0m $588.0m $581.0m
Amortization of Intangible Assets — $1.4b $1.2b $1.1b $1.0b $802.0m $732.0m $616.0m $588.0m $581.0m
Depreciation Expense $1.5b — — — — — — — — —
Amortization Cash Flow — — — — — — $732.0m $616.0m $588.0m $581.0m
Amortization Of Intangibles — — — — — — $732.0m $616.0m $588.0m $581.0m
Depreciation Amortization Depletion — — — — — — $1.3b $1.2b $1.1b $1.0b
Deferred Income Tax Expense (Benefit) — ($2.3b) ($895.0m) ($1.2b) ($350.0m) ($59.0m) ($1.1b) ($340.0m) ($418.0m) —
Deferred Income Taxes Net And Uncertain Tax Positions $15.0m — — — — — — — — —
Deferred Income Tax — — — — — — ($1.1b) ($317.0m) ($634.0m) ($671.0m)
Deferred Tax — — — — — — ($1.1b) ($317.0m) ($634.0m) ($671.0m)
Share-based Payment Arrangement, Noncash Expense — $133.0m $155.0m $119.0m $129.0m $119.0m $124.0m $121.0m $123.0m $157.0m
Equity Method Investment, Other than Temporary Impairment — — $0 — — — — — — —
Goodwill, Impairment Loss — $17.1b $3.0b — $4.6b $0 $2.0b $700.0m $1.3b $0
Impairment of Intangible Assets (Excluding Goodwill) — $3.2b $2.0b $1.6b $1.5b $424.0m $355.0m $350.0m $251.0m $259.0m
Impairment of Intangible Assets, Finite-lived — — — — — — — — — —
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) — — — $1.8b — — — — — —
Impairment of assets $1.6b — — — — — — — — —
Other-than-temporary impairment $140.0m — — — — — — — — —
Asset Impairment Charge — — — — — — $2.4b $1.1b $2.6b $1.0b
Gain (Loss) on Disposition of Assets — — — — — $7.0m $18.0m $25.0m — —
Gain (Loss) on Disposition of Business — $1.1b $67.0m $50.0m $8.0m $51.0m $46.0m $3.0m $15.0m ($22.0m)
Gain (Loss) on Disposition of Assets for Financial Service Operations — $11.0m $9.0m ($1.0m) $11.0m — — — $2.0m $2.0m
Income (Loss) from Equity Method Investments — ($3.0m) ($71.0m) ($13.0m) $138.0m $9.0m $21.0m $2.0m $1.0m $15.0m
Income Tax Expense (Benefit) — ($1.9b) ($195.0m) ($278.0m) ($168.0m) $211.0m ($638.0m) ($7.0m) $676.0m ($180.0m)
Interest Expense $290.0m — — — — — — — — —
Income Tax Expense $341.0m — — — — — — — — —
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Inventories — $199.0m $26.0m $271.0m $41.0m $380.0m ($163.0m) ($147.0m) $166.0m $152.0m
Proceeds from Stock Options Exercised — — — — — — — — $19.0m $47.0m
Deconsolidation, Gain (Loss), Amount — ($396.0m) — — — — — — — —
Foreign Currency Transaction Gain (Loss), before Tax — — — — — — — — — —
General and Administrative Expense — $1.5b $1.3b $1.2b $1.2b $1.1b $1.2b $1.2b $1.2b $1.3b
Goodwill — $28.4b $24.9b $24.8b $20.6b $20.0b $17.6b $17.2b $15.1b $16.0b
Inventory Write-down — — — — — — $4.2b — — —
Nonoperating Income (Expense) — ($895.0m) ($959.0m) ($822.0m) ($834.0m) ($1.1b) ($966.0m) ($1.1b) ($981.0m) ($934.0m)
Net change in operating assets and liabilities $1.2b — — — — — — — — —
Research and development in process $422.0m — — — — — — — — —
Stock-Based Compensation Expense $124.0m — — — — — — — — —
Other items ($14.0m) — — — — — — — — —
Purchases of investments and other assets ($481.0m) — — — — — — — — —
Proceeds from Investments $2.0b — — — — — — — — —
Stock Repurchases (Issuances) $329.0m — — — — — — — — —
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs ADSs $329.0m — — — — — — — — —
Purchase of treasury shares $0 — — — — — — — — —
Proceeds from Stock Issuance $35.0m — — — — — — — — —
Proceeds from long-term loans and other long-term liabilities, net of issuance costs $25.3b — — — — — — — — —
Repayment of long-term loans And Other Long Term Liabilities ($999.0m) — — — — — — — — —
Shares Issuance To Allergan plc for the Actavis Generics acquisition $5.1b — — — — — — — — —
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda $1.8b — — — — — — — — —
Actavis Generics Contingent Consideration $302.0m — — — — — — — — —
Trade Receivable $343.0m — — — — — — — — —
Inventories $372.0m — — — — — — — — —
Change in Other Working Capital ($517.0m) — — — — — — — — —
Trade payable accrued expenses employee related obligations and other current liabilities $640.0m — — — — — — — — —
Inventory Step Up $381.0m — — — — — — — — —
Beginning Cash Position — — — — — — $2.2b $2.8b $3.2b $3.3b
Cash Flow From Continuing Financing Activities — — — — — — ($1.5b) ($1.9b) ($1.8b) ($2.2b)
Cash Flow From Continuing Investing Activities — — — — — — $656.0m $968.0m $792.0m $737.0m
Change In Account Payable — — — — — — $2.0b $1.6b $258.0m ($15.0m)
Change In Inventory — — — — — — ($163.0m) ($147.0m) $166.0m $152.0m
Change In Other Current Assets — — — — — — ($828.0m) ($1.5b) ($1.1b) ($1.3b)
Change In Payable — — — — — — $2.0b $1.6b $258.0m ($15.0m)
Change In Payables And Accrued Expense — — — — — — $2.0b $1.6b $258.0m ($15.0m)
Change In Receivables — — — — — — $334.0m $12.0m $245.0m ($173.0m)
Change In Working Capital — — — — — — $1.4b ($72.0m) ($435.0m) ($1.4b)
Changes In Account Receivables — — — — — — $334.0m $12.0m $245.0m ($173.0m)
Changes In Cash — — — — — — $759.0m $423.0m $247.0m $235.0m
End Cash Position — — — — — — $2.8b $3.2b $3.3b $3.6b
Financing Cash Flow — — — — — — ($1.5b) ($1.9b) ($1.8b) ($2.2b)
Free Cash Flow — — — — — — $1.0b $842.0m $749.0m $1.1b
Gain Loss On Investment Securities — — — — — $104.0m $10.0m ($41.0m) — —
Gain Loss On Sale Of Business — — — — — — $10.0m ($41.0m) ($22.0m) $0
Gain Loss On Sale Of PPE — — — — — $104.0m $10.0m — — —
Interest Received CFI — — — — — — $1.1b $1.5b $1.3b $1.2b
Investing Cash Flow — — — — — — $656.0m $968.0m $792.0m $737.0m
Net Business Purchase And Sale — — — — — — $61.0m $68.0m $28.0m $34.0m
Net PPE Purchase And Sale — — — — — — ($548.0m) ($526.0m) ($498.0m) ($501.0m)
Operating Gains Losses — — — — — $104.0m $10.0m ($41.0m) ($22.0m) —
Other Non Cash Items — — — — — — ($91.0m) $61.0m $560.0m $81.0m
Purchase Of Business — — — — — — ($7.0m) $0 ($15.0m) $0
Purchase Of PPE — — — — — — ($548.0m) ($526.0m) ($498.0m) ($501.0m)
Sale Of Business — — — — — — $68.0m $68.0m $43.0m $34.0m
Stock Based Compensation — — — — — — $124.0m $121.0m $123.0m $157.0m
Other Operating Income (Expense), Net — — — $76.0m $40.0m $98.0m $107.0m $49.0m $14.0m ($18.0m)
Net Cash Provided by (Used in) Operating Activities $5.2b $2.2b $2.4b $748.0m $1.2b $798.0m $1.6b $1.4b $1.2b $1.6b
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment ($901.0m) $874.0m $651.0m $525.0m $578.0m $562.0m $548.0m ($526.0m) ($498.0m) ($501.0m)
Payments to Acquire Businesses, Net of Cash Acquired — ($43.0m) — — — — $7.0m $0 $15.0m $0
Acquisitions of businesses, net of cash acquired ($36.1b) — — — — — — — — —
Net Investment Purchase And Sale — — — — — — $3.0m ($46.0m) ($31.0m) ($15.0m)
Purchase Of Investment — — — — — — ($1.0m) ($46.0m) ($71.0m) ($57.0m)
Net (gain) loss from sale of long-lived assets and investments ($764.0m) — — — — — — — — —
Sale Of Investment — — — — — — $4.0m $0 $40.0m $42.0m
Payments for (Proceeds from) Other Investing Activities — $282.0m ($11.0m) ($58.0m) ($24.0m) ($1.0m) $0 $5.0m ($2.0m) ($5.0m)
Other investing activities ($212.0m) — — — — — — — — —
Net Other Investing Changes — — — — — $1.0m — ($5.0m) $2.0m $5.0m
Net Cash Provided by (Used in) Investing Activities ($35.7b) $3.4b $1.9b $1.4b $863.0m $1.5b $656.0m $968.0m $792.0m $737.0m
Cash flows from financing activities:
Issuance Of Debt — — — — — — $0 $3.2b $0 $2.3b
Long Term Debt Issuance — — — — — — $0 $2.5b $0 $2.3b
Net Issuance Payments Of Debt — — — — — — ($1.4b) ($1.7b) ($1.6b) ($1.8b)
Net Long Term Debt Issuance — — — — — — ($1.4b) ($1.7b) ($1.6b) ($1.8b)
Net Short Term Debt Issuance — — — — — — $0 $0 $0 $0
Short Term Debt Issuance — — — — — — $0 $700.0m $0 $0
Repayments of Long-term Debt — $3.3b $7.4b $3.9b $1.9b $6.6b $1.4b $4.2b $1.6b $4.1b
Long Term Debt Payments — — — — — — ($1.4b) ($4.2b) ($1.6b) ($4.1b)
Repayment Of Debt — — — — — — ($1.4b) ($4.9b) ($1.6b) ($4.1b)
Short Term Debt Payments — — — — — — $0 ($700.0m) $0 $0
Payments for Repurchase of Common Stock — — — — — — — — — —
Payments of Ordinary Dividends, Common Stock — $901 $12 — — — — — — —
Dividends paid on ordinary shares ($1k) — — — — — — — — —
Dividends paid on preferred shares ($255) — — — — — — — — —
Proceeds from (Payments for) Other Financing Activities — ($74.0m) ($57.0m) ($11.0m) ($5.0m) ($6.0m) ($118.0m) ($212.0m) ($8.0m) $41.0m
Other financing activities ($169.0m) — — — — — — — — —
Net Other Financing Charges — — — — — — ($118.0m) ($212.0m) ($150.0m) ($337.0m)
Net Cash from Financing Activities $2.0b — — — — — — — — —
Net Cash Provided by (Used in) Financing Activities $25.2b ($5.8b) ($3.4b) ($1.9b) ($1.9b) ($2.2b) ($1.5b) ($1.9b) ($1.8b) ($2.2b)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $54.0m ($142.0m) $16.0m $8.0m ($128.0m) ($123.0m) ($30.0m) ($174.0m) $21.0m
Effect of Exchange Rate on Cash ($660.0m) — — — — — — — — —
Effect Of Exchange Rate Changes — — — — — — ($123.0m) ($30.0m) ($174.0m) $21.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — ($25.0m) $819.0m $193.0m $202.0m $21.0m $636.0m $393.0m $74.0m $256.0m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $963.0m $1.8b $2.0b $2.2b $2.2b $2.8b $3.2b $3.3b $3.6b
Net change in cash and cash equivalents ($6.0b) — — — — — — — — —
Balance of cash and cash equivalents at beginning of period $988.0m — — — — — — — — —
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported — — — — — — $636.0m $393.0m $74.0m $256.0m
Interest Paid, Excluding Capitalized Interest, Operating Activities — $795.0m $815.0m $840.0m $846.0m $913.0m $948.0m $1.1b $1.0b $950.0m
Income Taxes Paid, Net — $106.0m $420.0m $552.0m $709.0m $495.0m $543.0m $298.0m $471.0m —

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.